↓ Skip to main content

Therapeutic Nuclear Medicine

Overview of attention for book
Cover of 'Therapeutic Nuclear Medicine'

Table of Contents

  1. Altmetric Badge
    Book Overview
  2. Altmetric Badge
    Chapter 668 Cyclotron-Based Radiopharmaceuticals for Nuclear Medicine Therapy
  3. Altmetric Badge
    Chapter 669 Rhenium-188 Generator-Based Radiopharmaceuticals for Therapy
  4. Altmetric Badge
    Chapter 670 Antibodies for Nuclear Medicine Therapy
  5. Altmetric Badge
    Chapter 671 Selective High Affinity Ligands: A New Class of Targeting Agents for Cancer Imaging and Therapy
  6. Altmetric Badge
    Chapter 672 Treatment of Progressive Dedifferentiated and Medullary Thyroid Cancer with Radiolabeled Somatostatin Analogs
  7. Altmetric Badge
    Chapter 673 Radioiodine Therapy of Hyperthyroidism (Toxic Goiter, Hyperfunctioning Nodule) and Non-Toxic Goiter: Procedures and Guidelines
  8. Altmetric Badge
    Chapter 674 Radioiodine Therapy of Hyperthyroidism in Graves’ Disease
  9. Altmetric Badge
    Chapter 675 Radionuclide Therapy of Bone Metastases Using Rhenium-188 Hydroxyethylidene Diphosphonate
  10. Altmetric Badge
    Chapter 676 Radionuclide Therapy for Bleeding Joints in Hemophilia
  11. Altmetric Badge
    Chapter 677 Yttrium-90 Labelled Anti-CD20 Radioimmunotherapy with Stem Cells Support
  12. Altmetric Badge
    Chapter 678 Therapeutic Nuclear Medicine
  13. Altmetric Badge
    Chapter 679 Radioimmunotherapy of Tumors: Pretargeting with Bispecific Antibodies
  14. Altmetric Badge
    Chapter 680 Radioimmunotherapy in Metastatic Colorectal Cancer
  15. Altmetric Badge
    Chapter 681 Myeloablative Radioimmunotherapy in Conditioning of Acute Leukemia, MDS, and Multiple Myeloma Prior to Hematological Stem Cell Transplantation
  16. Altmetric Badge
    Chapter 682 Endovascular Brachytherapy to Prevent Restenosis After Percutaneous Coronary Intervention
  17. Altmetric Badge
    Chapter 683 Locoregional Radionuclide Therapy of Primary and Metastatic Cancers
  18. Altmetric Badge
    Chapter 684 Patient-Specific Dosimetry, Radiobiology, and the Previously-Treated Patient
  19. Altmetric Badge
    Chapter 685 Comparison Between β -Emitting Isotopes and α -Emitters Regarding Their Effects on Cancer Cells
  20. Altmetric Badge
    Chapter 686 Hormesis by Low Dose Radiation Effects: Low-Dose Cancer Risk Modeling Must Recognize Up-Regulation of Protection
  21. Altmetric Badge
    Chapter 687 Dosimetry in Accidental Radiation Exposure
  22. Altmetric Badge
    Chapter 688 Potential Impact of Radiation Biology in Radiation Protection in Nuclear Medicine and Corresponding Regulatory Issues
  23. Altmetric Badge
    Chapter 689 PET for Radiotherapy Planning
  24. Altmetric Badge
    Chapter 690 Hypoxia Imaging for Radiation Therapy Planning
  25. Altmetric Badge
    Chapter 692 Radiopeptide Therapy of Brain Tumors
  26. Altmetric Badge
    Chapter 693 Intracavitary Use of Radionuclides and Treatment of Meningiomas
  27. Altmetric Badge
    Chapter 694 Ablation Therapy with Radioiodine in Adults and Children with Differentiated Thyroid Cancer
  28. Altmetric Badge
    Chapter 695 Medullary Thyroid Carcinoma
  29. Altmetric Badge
    Chapter 697 Economic and Industrial Considerations for Marketing of Therapeutic Radiopharmaceuticals
  30. Altmetric Badge
    Chapter 698 Pharma Considerations for Timely Development of Therapeutic Radiopharmaceuticals
  31. Altmetric Badge
    Chapter 704 Inorganic Radionuclides for Nuclear Medicine Therapy
  32. Altmetric Badge
    Chapter 709 Fractionated Radioimmunotherapy of Non-Hodgkin Lymphoma with 90-Y-Labeled Anti-CD22 Antibody, Epratuzumab Tetraxetan
  33. Altmetric Badge
    Chapter 710 Radioimmunotherapy of Renal Cancer
  34. Altmetric Badge
    Chapter 711 Dosimetry for Peptide Receptor Radionuclide Therapy
  35. Altmetric Badge
    Chapter 712 Radionuclide Therapy for Skin Malignancies
  36. Altmetric Badge
    Chapter 713 Monte Carlo Methods in Nuclear Medicine
  37. Altmetric Badge
    Chapter 714 Animal Models for Developing Radiopharmaceuticals for Therapy
  38. Altmetric Badge
    Chapter 715 PET for Measuring Therapy Response After Radionuclide Therapy
  39. Altmetric Badge
    Chapter 716 Developing Probes for Molecular Imaging
  40. Altmetric Badge
    Chapter 727 Radioembolization (Yttrium-90 Microspheres) for Metastatic Hepatic Malignancies
  41. Altmetric Badge
    Chapter 730 Radioimmunotherapy of Brain Tumors
  42. Altmetric Badge
    Chapter 731 Sodium Iodide Symporter in Thyroid Carcinoma
  43. Altmetric Badge
    Chapter 732 Radio-Tympano-Sinu-Orthesis as a Treatment Option in Chronic Otitis Media and Paranasal Mucositis
  44. Altmetric Badge
    Chapter 733 Radioembolization: Clinical Results Hepatocellular Carcinoma
  45. Altmetric Badge
    Chapter 734 Treatment of Lymphoma with 131 I-Chimeric Monoclonal Antibodies
  46. Altmetric Badge
    Chapter 735 Non-Hodgkin’s Lymphoma High Dose Therapy
  47. Altmetric Badge
    Chapter 736 Effects of Music on the Psyche of Neuroendocrine Tumour Patients Undergoing Peptide Receptor Radionuclide Therapy
  48. Altmetric Badge
    Chapter 737 Nuclear Medicine Dose Assessment
  49. Altmetric Badge
    Chapter 738 Radiation Protection of Staff and Public
  50. Altmetric Badge
    Chapter 739 The Use of Dosimetry in the Planning of Patient Therapy
  51. Altmetric Badge
    Chapter 740 Chemotherapy Combined with Radionuclide Therapy
  52. Altmetric Badge
    Chapter 741 Gene Expression Analysis by DNA Microarray in Papillary and Follicular Differentiated Thyroid Cancer
  53. Altmetric Badge
    Chapter 742 Redifferentiation Therapy in Thyroid Cancer
  54. Altmetric Badge
    Chapter 743 Maximal Safe Dose Method of I-131 in the Management of Recurrent/Metastatic Differentiated Thyroid Carcinoma
  55. Altmetric Badge
    Chapter 744 Therapeutic Strategy of Papillary Microcarcinoma of the Thyroid Gland: A Nuclear Medicine Perspective
  56. Altmetric Badge
    Chapter 745 UICC Classifications 1997, 2002 and 2009: What is the Impact on Thyroid Cancer Mangement?
  57. Altmetric Badge
    Chapter 746 Follow-up of Thyroid Cancer Patients and Treatment of Distant Metastases
  58. Altmetric Badge
    Chapter 778 Epidermal Radionuclide Therapy: Dermatological High-Dose-Rate Brachytherapy for the Treatment of Basal and Squamous Cell Carcinoma
  59. Altmetric Badge
    Chapter 782 Therapeutic Radionuclides: Production, Physical Characteristics, and Applications
  60. Altmetric Badge
    Chapter 783 New Approaches: Combined Local and Multimodal Strategies in the Treatment of Complex Neuroendocrine Liver Metastases
  61. Altmetric Badge
    Chapter 784 I-131 Meta Iodobenzylguanidine Therapy
  62. Altmetric Badge
    Chapter 785 Radiolabelled Bisphosphonates for Bone Pain Palliation
  63. Altmetric Badge
    Chapter 786 Targeted Radionuclide Therapy of Prostate Cancer
  64. Altmetric Badge
    Chapter 793 Radioembolization: Concepts and Procedures
  65. Altmetric Badge
    Chapter 807 Rhenium-188 Lipiodol for the Treatment of Hepatocellular Carcinoma (HCC)
  66. Altmetric Badge
    Chapter 808 Role of Surgery in a Multidisciplinary Approach
  67. Altmetric Badge
    Chapter 819 Treatment of Osteoblastic Skeletal Metastases by the Alpha-Emitting Bone-Seeker Radium-223
  68. Altmetric Badge
    Chapter 823 Radionuclide Therapy of Inflammatory Joint Diseases (Radiation Synovectomy, Radiosynoviorthesis)
  69. Altmetric Badge
    Chapter 828 Radioimmunotherapy of Neuroblastoma
  70. Altmetric Badge
    Chapter 872 Radioiodine Remnant Ablation: A Critical Review
  71. Altmetric Badge
    Chapter 918 A Historical Perspective on the Use of Radionuclides for Therapy
  72. Altmetric Badge
    Chapter 921 Peptides for Nuclear Medicine Therapy: Chemical Properties and Production
  73. Altmetric Badge
    Chapter 943 Non-Hodgkin Lymphoma: Radioimmunotherapy Using Iodine-131 Labeled Murine Anti-CD20 Antibodies ( 131 I-Tositumomab and Tositumomab, “Bexxar”)
  74. Altmetric Badge
    Chapter 945 Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors Expressing Somatostatin Receptors
  75. Altmetric Badge
    Chapter 946 Generator-Based Radiopharmaceuticals for PET Dosimetry Before, During, and After Endoradiotherapy
Attention for Chapter 686: Hormesis by Low Dose Radiation Effects: Low-Dose Cancer Risk Modeling Must Recognize Up-Regulation of Protection
Altmetric Badge

Mentioned by

twitter
2 X users

Citations

dimensions_citation
22 Dimensions

Readers on

mendeley
13 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
Hormesis by Low Dose Radiation Effects: Low-Dose Cancer Risk Modeling Must Recognize Up-Regulation of Protection
Chapter number 686
Book title
Therapeutic Nuclear Medicine
Published by
Springer, Berlin, Heidelberg, January 2012
DOI 10.1007/174_2012_686
Book ISBNs
978-3-54-036718-5, 978-3-54-036719-2
Authors

Ludwig E. Feinendegen, Myron Pollycove, Ronald D. Neumann, Feinendegen, Ludwig E., Pollycove, Myron, Neumann, Ronald D.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 13 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 13 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 3 23%
Student > Bachelor 2 15%
Lecturer > Senior Lecturer 1 8%
Student > Ph. D. Student 1 8%
Student > Doctoral Student 1 8%
Other 2 15%
Unknown 3 23%
Readers by discipline Count As %
Environmental Science 4 31%
Physics and Astronomy 3 23%
Agricultural and Biological Sciences 1 8%
Medicine and Dentistry 1 8%
Unknown 4 31%